Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rwr veterinary products pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

chemvet australia pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - ivermectin - unknown - ivermectin anthelmintic active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - ivermectin, quantity: 10 mg/g - cream - excipient ingredients: glycerol; isopropyl palmitate; carbomer copolymer (type b); dimeticone 20; disodium edetate; citric acid monohydrate; cetyl alcohol; stearyl alcohol; ceteareth-20; sorbitan stearate; methyl hydroxybenzoate; propyl hydroxybenzoate; phenoxyethanol; propylene glycol; oleyl alcohol; sodium hydroxide; purified water - soolantra is indicated for the topical treatment of inflammatory lesions of rosacea (papulo-pustular) in adult patients 18 years and over.

United States - English - NLM (National Library of Medicine)

edenbridge pharmaceuticals llc. - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin is indicated for the treatment of the following infections: ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite strongyloides stercoralis . this indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (see clinical pharmacology, clinical studies ). ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite onchocerca volvulus . this indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of west africa. the comparative studies used diethylcarbamazine citrate (dec-c). note: ivermectin has no activity against adult onchocerca volvulus parasites. the adult parasites reside in subcutaneous nodules which are infrequently palpable. surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. ivermectin tablets are contraindicated in patients who are hypersensitive to any component of this product.

United States - English - NLM (National Library of Medicine)

prasco laboratories - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin cream is indicated for the treatment of inflammatory lesions of rosacea. none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. ivermectin cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. note: the animal multiples of human exposure calculations were based on auc comparisons. the maximum topical human dose (mthd) of ivermectin cream is 1 g applied once daily. systemic embryofetal development studies were conducted in rats and rabbits. oral doses of 1.5, 4, and 12 mg/kg/day ivermectin were administered during the period of organogenesis (gestational days 6–17) to pregnant female rats. maternal death occurred at 12 mg/kg/day (1909x mthd). cleft palate occurred in the fetuses from the 12 mg/kg/day (1909x mthd) group. no treatment related effects on embryofetal toxicity or teratogenicity were noted at 4 mg/kg/day (708x mthd). oral doses of 0.5, 1.5, 2.5, 3.5 and 4.5 mg/kg/day ivermectin were admin

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. none. risk summary the available data on the use of ivermectin, including ivermectin cream, in pregnant women are insufficient to establish a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, ivermectin induced adverse developmental outcomes when orally administered to pregnant rats and rabbits during the period of organogenesis at doses 1909 or 354 times the maximum recommended human dose (mrhd), respectively. these orally administered doses were maternally toxic to pregnant rats and rabbits. in a pre-and postnatal developmental study in rats, neonatal toxicity and adverse effects on behavioral development were observed when ivermectin was orally administered to pregnant females during gestation and lactation (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a